« back

NIHR Efficacy and Mechanism Evaluation (EME) Programme funds -NIHR: Evaluating the Efficacy of Metformin in Tuberous Sclerosis Complex

  Tuesday, 25 Apr 2023 | Funding Deadline

The Efficacy and Mechanism Evaluation (EME) Programme funds ambitious studies evaluating interventions with potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research in the mechanisms of diseases and treatments. EME is a partnership between the Medical Research Council (MRC) and the NIHR.

Through this call, the MRC-NIHR EME programme is inviting applications to conduct further research regarding the therapeutic value of metformin in patients with Tuberous Sclerosis Complex. The proposed trial should aim to definitively establish whether or not metformin is safe and efficacious. If the findings are positive, the Medicines Repurposing Programme would subsequently aim to facilitate an application for a licence variation from the medicines regulator, MHRA.

Deadline for proposals: 25 April 2023
Find out more here